Get the Daily Brief
Latest Biotech News
Tenpoint wins FDA nod for dual‑agent presbyopia drop and secures $235M
The FDA approved Tenpoint Therapeutics’ Yuvezzi, the first dual‑agent eye drop for presbyopia combining carbachol and brimonidine. Tenpoint also closed $235 million in combined equity and debt...
Lilly builds capacity for obesity era: $3.5B Lehigh Valley factory
Eli Lilly unveiled plans for a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, intended to produce its next‑generation obesity injectable retatrutide and other weight‑loss...
DeepMind’s AlphaGenome maps non‑coding DNA: regulatory variant predictions
DeepMind published AlphaGenome, a large sequence model designed to predict the functional effects of variants across the non‑coding 'dark' genome. The model takes long DNA contexts (up to one...
Ultragenyx resubmits Sanfilippo AAV therapy: FDA re‑filing after rejection
Ultragenyx resubmitted its biologics license application for UX111, an AAV gene therapy candidate for Sanfilippo syndrome type A, after the FDA rejected the original filing last summer. The...
AstraZeneca vows $15B China push—R&D and manufacturing expansion
AstraZeneca announced a multi-billion-dollar expansion in China and struck a high-value collaboration to broaden its obesity and diabetes pipeline. The company committed more than $15 billion...
Lilly builds $3.5B factory—retatrutide and next-gen obesity drugs slated
Eli Lilly disclosed a $3.5 billion manufacturing investment to produce its next-generation obesity injectables, including retatrutide, at a new Lehigh Valley facility. The plant will house both...
Tenpoint wins FDA nod—dual-agent presbyopia drop cleared and $235M secured
Tenpoint Therapeutics won U.S. FDA approval for Yuvezzi, a combination eye drop for adult presbyopia, and announced financing to support commercialization. The FDA clearance makes Yuvezzi the...
Illumina closes SomaLogic buy—proteomics and CLIA lab fold into NGS leader
Illumina completed its acquisition of SomaLogic and related assets from Standard BioTools for $350 million in cash plus contingent payments, expanding Illumina’s footprint in proteomics and...
NanoMosaic wins FDA AMT—nanoneedle QC platform fast-tracked for gene therapy
NanoMosaic secured an FDA Advanced Manufacturing Technology (AMT) designation for its Nanoneedle/Tessie platform, marking regulatory recognition of a high‑throughput QC assay for AAV gene therapy...
Beckman Coulter and Automata pair up—Danaher joins Automata’s Series C
Beckman Coulter Life Sciences announced a strategic partnership with lab‑automation firm Automata to integrate liquid‑handling and genomics instruments into Automata’s LINQ automation ecosystem;...
DeepMind publishes AlphaGenome—AI models the regulatory 'dark genome'
DeepMind released AlphaGenome (also reported as Alphagenome), an AI system designed to predict the functional effects of noncoding regulatory variants across long DNA sequences. The model...
Repertoire inks $1.92B autoimmune pact with Lilly—tolerizing vaccines push forward
Repertoire Immune Medicines signed a multi‑billion‑dollar partnership with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving an $85 million upfront payment and up to...
Grail files Galleri for FDA premarket approval—large multi-study evidence package
Grail submitted its Galleri multi‑cancer early detection test to the U.S. FDA seeking premarket approval, citing performance and safety data from more than 25,000 patients in Pathfinder 2 and...
Phase III failure collapses Quince—monthly steroid therapy for A‑T halted
Quince Therapeutics disclosed top‑line results from its pivotal Neat Phase III trial of eDSP (dexamethasone sodium phosphate encapsulated in autologous erythrocytes) for ataxia‑telangiectasia...
AstraZeneca bankrolls CSPC: up to $18.5B for next‑gen obesity drugs
AstraZeneca struck a landmark licensing and strategic collaboration with China’s CSPC Pharmaceutical Group to acquire global rights to an eight‑program obesity and type 2 diabetes portfolio. The...
FDA clears duo‑drop: Tenpoint wins approval and $235M to commercialize Yuvezzi
The U.S. Food and Drug Administration approved Tenpoint Therapeutics’ Yuvezzi, a dual‑agent ophthalmic solution (carbachol and brimonidine) for adult presbyopia, marking the first FDA‑cleared...
FDA grants AMT: NanoMosaic’s nanoneedle QC platform wins regulatory fast‑track
The FDA’s Center for Biologics Evaluation and Research granted Advanced Manufacturing Technology (AMT) designation to NanoMosaic for its nanoneedle/Tessie platform used to multiplex genome and...
Beckman Coulter integrates with Automata — Danaher backs automation scale‑up
Beckman Coulter Life Sciences and London‑based Automata announced a strategic partnership to integrate Beckman liquid‑handling and genomic instruments into Automata’s LINQ AI‑ready automation...
Eli Lilly bets on Repertoire: $1.9B autoimmune collaboration validates Decode platform
Repertoire Immune Medicines signed a collaboration with Eli Lilly to develop tolerizing therapies for multiple autoimmune diseases. Financial terms include an $85 million upfront payment and up to...
Phase‑III fizzle topples Quince: steroid therapy fails in ataxia trial
Quince Therapeutics disclosed that its pivotal Phase III NEAT trial of dexamethasone sodium phosphate encapsulated in autologous erythrocytes (eDSP) in ataxia‑telangiectasia failed to meet the...